Knight Therapeutics Stock Today
| GUD Stock | CAD 5.27 0.02 0.38% |
Performance0 of 100
| Odds Of DistressLess than 13
|
Knight Therapeutics is selling at 5.27 as of the 26th of November 2024; that is 0.38% down since the beginning of the trading day. The stock's open price was 5.29. Knight Therapeutics has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Knight Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Category Healthcare |
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company was incorporated in 2013 and is headquartered in Montreal, Canada. KNIGHT THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange.. More on Knight Therapeutics
Moving against Knight Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Knight Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Knight Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Knight Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Jonathan Goodman | ||||
| Business Concentration | Drug Manufacturers - Specialty & Generic, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
Knight Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Knight Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Knight Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Knight Therapeutics' financial leverage. It provides some insight into what part of Knight Therapeutics' total assets is financed by creditors.
| |||||
Knight Therapeutics (GUD) is traded on Toronto Exchange in Canada and employs 725 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 576.83 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Knight Therapeutics's market, we take the total number of its shares issued and multiply it by Knight Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Knight Therapeutics operates under Pharmaceuticals sector and is part of Health Care industry.
Knight Therapeutics has accumulated about 302 K in cash with 28.49 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.1.
Check Knight Therapeutics Probability Of Bankruptcy
Knight Therapeutics Risk Profiles
Although Knight Therapeutics' alpha and beta are two of the key measurements used to evaluate Knight Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.28 | |||
| Standard Deviation | 2.12 | |||
| Variance | 4.5 | |||
| Risk Adjusted Performance | (0.03) |
Knight Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Knight Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Knight Therapeutics Corporate Directors
| Robert Lande | Independent Director | Profile | |
| Nancy Harrison | Independent Director | Profile | |
| Sylvie Tendler | Independent Director | Profile | |
| Meir Jakobsohn | Director | Profile |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.